Prospect of best selling drugs and hot treatment fields in 2015 (with ranking of drug market potential in 2015)

Source: Xinkangjie 2014-12-15 for those who want to find innovation in the pharmaceutical industry, 2015 will have a good omen Next year, it is estimated that there will be more than a dozen products that will become heavy bombs in 2020 These new drugs have a huge field of treatment, especially in cardiovascular and respiratory systems Because of the broad prospect of immunotherapy, including detection point inhibitors, they will be used in clinical and diagnosis, which indicates that next year will also be a big year for tumor drugs Patent drug expiration is at a low ebb next year, which is also a very important reason for evaluatepharma to be optimistic about the pharmaceutical industry next year Only Copaxone, a heavyweight product of TIWA, and Anli (aripiprazole) of Otsuka pharmaceutical in Japan will face the competition of generic drugs According to the analysis of evaluate Pharma, the loss caused by patent expiration is only one third of that of this year next year, compared with 2011, which is only a drop in the bucket Since this year, investor sentiment has been clearly encouraged by the pharmaceutical industry, as evidenced by the soaring pharmaceutical stock index This pursuit of medicine stocks has not seen the enthusiasm subside at the end of this year, and it seems that it will continue to blow in 2015 The only thing that will feel bad next year is global health care payments, where consumers are increasingly clamoring to limit drug prices At the same time, next year's M & A in the pharmaceutical industry will not stop, at least it will maintain this year's level Large pharmaceutical enterprises like Pfizer will still appear in the pharmaceutical industry due to the wave of asset transfer brought about by tax issues In 2014, there have been mergers and acquisitions with a total value of more than 200 billion US dollars, which is also the largest year since 2000, including two large-scale mergers and acquisitions However, as long as the stock market remains trading exuberant, we don't need to worry too much, and the financial environment and stock market can remain friendly All in all, 2015 will be a big year for the pharmaceutical industry The following are the heavyweight products to be approved next year, with the shadow of 2013 looming In that year, we have seen the market potential of sovaldi, tecbidera, imbruvica and kadcyla According to the analysis of the analyst of evaluate Pharma, the most potential new drug is PD1 inhibitor (trade name: opdivo) of cellular immunotherapy used by Bristol Myers Squibb for cancer treatment The drug will be listed in Europe and the United States The sales scale in 2015 is expected to reach 658 million dollars, and the sales scale in 2020 will reach 7.122 billion dollars In addition to opdivo, other potential new drugs (US $100 million) to be approved in 2015 will be the next big thing for 2015, which will be a more relaxed regulation and a higher level of new drug approval At the same time, these drugs that have entered the market will continue to follow up to see if they meet the clinical expectations Here are the analysts' forecasts for the top 10 drugs to be sold next year In 2015, sovaldi, the top-selling drug (US $1 billion), was launched less than a year ago It was a great success and inspired the whole pharmaceutical industry Although sovaldi and harvoni, another hepatitis C treatment drug developed by Gilead, occupy the top position in 2015, their good fortune will not last until 2020 According to the analysis of evaluate Pharma, Humira will return to the top position in 2020 The most popular drugs in 2020 are the top 1 billion US dollars Most of the drugs with considerable sales focus on the extremely valuable treatment field One obvious example is that the most promising treatment field we have seen so far in 2015 is type 2 diabetes Although there is only one product in the top 10 best selling drugs in 2015, we have DPP4 inhibitors and GLP1 Agonists have been on the market in the past year, which will be a potential area for the next period of time With the increasing incidence rate of type two diabetes, there is no doubt that despite the increased competition in the field and the pressure of price pressure, the attraction of the disease field to pharmaceutical companies will continue for some time, and the ten indications in 2015 (100 million US dollars) Of course, from the perspective of the growth of market scale in the treatment field, the treatment field with the fastest growth is not among the above ten treatment fields 5 treatment areas with the fastest growth of market scale in 2015-2020 (US $100 million)